Ambitious Stroke Tech NovaSignal focuses on real-time cerebral blood flow analysis with autonomous transcranial Doppler exams via the NG2 platform, presenting a compelling value proposition to hospitals, stroke centers, ASCs, and rural clinics seeking faster, data-driven stroke prevention.

Regulatory & Reimbursement NG2 is fully reimbursable under existing CPT codes (93886, 93892, 93893), reducing payer friction and enabling quicker adoption by healthcare providers evaluating new neuroimaging solutions.

Clinical Impact Advantage NG2 detects three times more PFOs and identifies nearly three times as many treatable shunts compared with standard methods, offering a strong clinical differentiator that can drive hospital partnerships and referral networks.

Expansion Opportunity With a small-medical team (11-50 employees) and a scalable cloud/AI-enabled platform, target expansion into stroke centers, rural clinics, and ambulatory surgery centers that need remote-access brain imaging and automated diagnostics.

Growth & Collaboration Recent NG2 launch signals momentum and potential for strategic partnerships, channeling conversations with larger medical device and neuroimaging firms; align with prospective distributors or integrators to accelerate market penetration.